Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Mar 29, 2024
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.
Read more at globenewswire.com
